Li, Dateng
Xu, Meng
Hooper, Andrea T.
Rofail, Diana
Mohammadi, Kusha A.
Chen, Yiziying
Ali, Shazia
Norton, Thomas
Weinreich, David M.
Musser, Bret J.
Hamilton, Jennifer D.
Geba, Gregory P.
Funding for this research was provided by:
Regeneron Pharmaceuticals
Article History
Received: 21 December 2022
Accepted: 28 July 2023
First Online: 7 August 2023
Competing interests
: DL and YC are former employees of Regeneron Pharmaceuticals, Inc. and current stockholders. MX is an employee/stockholder of Regeneron Pharmaceuticals, Inc., is a current Pfizer, Inc. stockholder, and reports grants from University of Minnesota, MN, and University of Haifa, Israel. ATH is an employee/stockholder of Regeneron Pharmaceuticals, Inc., is a former Pfizer, Inc. employee and current stockholder, and has a patent pending with Regeneron Pharmaceuticals, Inc. DR is an employee/stockholder of Regeneron Pharmaceuticals, Inc., and is a former F. Hoffmann-La Roche AG employee and current stockholder. KAM is an employee/stockholder of Regeneron Pharmaceuticals, Inc., reports grants from the University of Texas Health Science Center, Houston, and has received consulting fees from Safen Medical Products. SA, TN, DMW, BJM, and GPG are employees/stockholders of Regeneron Pharmaceuticals, Inc. JDH is an employee/stockholder of Regeneron Pharmaceuticals, Inc., and has a patent pending, which has been licensed and receiving royalties, with Regeneron Pharmaceuticals, Inc.